September 23rd 2024. SHUTEs polymer optical fibers are implanted in humans for the first time. 

One of SHUTE's longest running customers Synergia Medical this week announced that they had reached the incredible milestone to begin clinical tests on two human patients.

SHUTE has since 2018 been working closely with Synergia Medical on the development of high-tech polymer fibers for inner body usage. Fibers that are now patented.  

Synergia Medical has developed NAO.VNS (Vagus Nerve Stimulation), the first non-metal optoelectronic neurostimulator for the treatment of drug-resistant epilepsy.

The device includes a small nonmetallic encapsulation, wireless fast charging, custom optical lead, photovoltaic cells, and an enhanced electrode.

These first human trials include SHUTEs polymer fiber as a key component in the device.

“We at SHUTE are of course very proud of our small contribution in making life with epilepsy more bearable.” Says SHUTE CTO Kristian Nielsen

For more information about this revolutionary product and clinical trials, please visit Synergia Medical and for more information on the product here and the implant here.

Synergia Medical SHUTE 3